Prosecution Insights
Prosecution Insights
8 pending office actions • 1 client • 7 examiners • 5 art units • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (75%) |
| No statute on record | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, QUYNH-NHU HOANG | 2 | 68.2% | +27.9% |
| GILL, RACHEL B | 1 | 65.6% | +27.7% |
| OSINSKI, BRADLEY JAMES | 1 | 78.5% | +11.3% |
| KIM, SUN U | 1 | 78.5% | +11.1% |
| JACKSON-TONGUE, LAKIA J | 1 | 68.8% | +20.4% |
| RODRIGUEZ, CRIS LOIREN | 1 | 20.0% | +9.8% |
| BUCKMASTER, MARLENE VRENI | 1 | 25.9% | +74.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17720025 | Methods of Inducing Immune Response Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern | BUCKMASTER, MARLENE VRENI | 50d overdue |
| 17855349 | Side-Port Injection Devices For Use With Electroporation, and Related Systems and Methods | RODRIGUEZ, CRIS LOIREN | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18302522 | METHOD AND DEVICE FOR MINIMALLY INVASIVE IN VIVO TRANSFECTION OF ADIPOSE TISSUE USING ELECTROPORATION | KIM, SUN U | 100d overdue |
| 17720025 | Methods of Inducing Immune Response Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern | BUCKMASTER, MARLENE VRENI | 50d overdue |
| 16804707 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD | VU, QUYNH-NHU HOANG | 37d overdue |
| 18339387 | INTRADERMAL INJECTION DEVICE | VU, QUYNH-NHU HOANG | 16d overdue |
| 18468041 | Vacuum-Assisted Treatment Device, and Related Systems and Methods | OSINSKI, BRADLEY JAMES | 9d |
| 18060048 | IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT | JACKSON-TONGUE, LAKIA J | 12d |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | GILL, RACHEL B | 34d |
| Client (Assignee) | Pending OAs |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | 8 |
| Art Unit | Apps |
|---|---|
| 3783 | 4 |
| 1671 | 1 |
| 1777 | 1 |
| 1645 | 1 |
| 1672 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | Inovio Pharmaceuticals, Inc. | GILL, RACHEL B | 1671 | Other | Non-Final OA | 34d | Pending | Oct 24, 2023 |
| 18468041 | Vacuum-Assisted Treatment Device, and Related Systems and Methods | Inovio Pharmaceuticals, Inc. | OSINSKI, BRADLEY JAMES | 3783 | §103 | Non-Final OA | 9d | Pending | Sep 15, 2023 |
| 18339387 | INTRADERMAL INJECTION DEVICE | Inovio Pharmaceuticals, Inc. | VU, QUYNH-NHU HOANG | 3783 | Other | Final Rejection | 16d overdue | Pending | Jun 22, 2023 |
| 18302522 | METHOD AND DEVICE FOR MINIMALLY INVASIVE IN VIVO TRANSFECTION OF ADIPOSE TISSUE USING ELECTROPORATION | Inovio Pharmaceuticals, Inc. | KIM, SUN U | 1777 | §103 | Non-Final OA | 100d overdue | Pending | Apr 18, 2023 |
| 18060048 | IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT | Inovio Pharmaceuticals, Inc. | JACKSON-TONGUE, LAKIA J | 1645 | §103 | Final Rejection | 12d | Pending | Nov 30, 2022 |
| 17855349 | Side-Port Injection Devices For Use With Electroporation, and Related Systems and Methods | Inovio Pharmaceuticals, Inc. | RODRIGUEZ, CRIS LOIREN | 3783 | §103 | Non-Final OA | 5d overdue | Pending | Jun 30, 2022 |
| 17720025 | Methods of Inducing Immune Response Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern | Inovio Pharmaceuticals, Inc. | BUCKMASTER, MARLENE VRENI | 1672 | §103 | Final Rejection | 50d overdue | Pending | Apr 13, 2022 |
| 16804707 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD | Inovio Pharmaceuticals, Inc. | VU, QUYNH-NHU HOANG | 3783 | §103 | Non-Final OA | 37d overdue | Pending | Feb 28, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial